Top Story

Non–infarct-related artery disease common in patients with STEMI

November 28, 2014

Results from a retrospective pooled analysis of eight clinical trials suggest that obstructive non–infarct-related artery disease is common in patients who present with STEMI, and it may increase the risk for 30-day mortality.

Researchers evaluated data on 68,765 patients extracted from eight independent, international, randomized clinical trials of STEMI published from 1993 to 2007. They examined demographics, clinical risk factors, comorbidities, cardiac manifestations, hemodynamic status and left ventricular function, angiographic information regarding infarct-related artery disease and non–infarct-related artery disease for each vessel territory, in-hospital medications and mortality data. Angiographic data were available for 28,282 patients.

Meeting News Coverage

Physical activity program did not prevent CV events in older adults

November 26, 2014
CHICAGO — A structured physical activity program had no effect on CV events in older adults compared with a health education program, according to new data from…
FDA clears FFR-CT system for marketing FDA News

FDA clears FFR-CT system for marketing

November 26, 2014
The FDA announced that it has cleared for marketing a software system to compute fractional flow reserve from noninvasive CT angiography. The FFR-CT system (HeartFlow…
Meeting News Coverage

WOSCOPS: 20-year follow-up demonstrates clinical benefit of statins in men

November 26, 2014
CHICAGO — At 20 years, men assigned statin therapy during the 5-year West of Scotland Coronary Prevention Study had lower rates for mortality and CV events…
Doug Mann Meeting News Coverage

AUGMENT-HF: Novel implantable device safe, effective in patients with advanced HF

November 26, 2014
CHICAGO — A novel implantable device was administered safely and associated with clinical benefit in patients with advanced HF, according to phase 2 trial data…
More News Headlines »
Risk Management in the Cardiovascular Disease Arena

Risk Management in the Cardiovascular Disease Arena: Focus on Glycemic Control

This activity is supported by an educational grant from Genentech.

Among the multiple comorbidities and complications that are associated with type 2 diabetes mellitus (T2DM)…
More »
Meeting News Coverage Video
thumbnail for video 3907832195001

Anna Axelsson, MD: Results from INHERIT do not 'close the door' on losartan

November 24, 2014
CHICAGO — While results from the INHERIT trial indicate that losartan had no effect on left ventricular mass or…
More »
Experts Take: Dialogue on HTG

Experts’ Take: Dialogue on Hypertriglyceridemia

This activity is supported by an independent educational grant from Amarin Pharma Inc.

Lead by genetic studies, recent data describe a causal role of triglycerides (TG) in the formation of atherosclerosis…
More »